To the Editor—Infections caused by New Delhi metallo-β lactamase 1 (NDM-1)–producing Enterobacteriaceae are reported to have a significantly higher likelihood of in-hospital mortality [1]. Previous evidence showed that NDM-producing bacteria are often susceptible to colistin, which has become the last resort for the treatment of infections due to NDM-producing bacteria [2]. However, the plasmid-mediated colistin resistance (MCR-1) gene, was first identified in Enterobacteriaceae recently [3]. Therefore, patients ultimately might receive only extremely limited drug options [4]. Here, we characterize for the first time 2 clonally unrelated Escherichia coli strains co-producing MCR-1 and NDM-1, which were recovered from 2 patients with bloodstream infection.

Patient 1 was a 10-day-old male infant who was admitted to the Affiliated Hospital of Jining Medical University, China, due to fever and difficulty breathing. Blood culture demonstrated growth of E. coli strain EC1002. He was diagnosed with neonatal sepsis and treated with levofloxacin and amoxicillin-clavulanic acid. Patient 2 was a 56-year-old man who suffered a traffic accident and was admitted to the Anhui Provincial Hospital, China. An E. coli strain EC2474 was recovered from the blood culture. Both patients showed clinical improvement after antibiotic therapy and were discharged after lengthy hospital stays.

Antimicrobial susceptibility revealed that EC1002 had a high-level resistance to carbapenems, cephalosporins, and aminoglycosides, but was susceptible to quinolones and tigecycline. Meanwhile, EC2474 was resistant to all antibiotics tested, except tigecycline (Table 1). Clonal diversity was assessed by pulsed-field gel electrophoresis (PFGE), which demonstrated that both isolates were clonally unrelated (Supplementary Data). Multilocus sequence typing indicated that EC1002 belonged to sequence type (ST) 2373 and EC2474 was ST131. Polymerase chain reaction and sequencing identified both isolates encoding the MCR-1, blaNDM-1, and blaCTX-M-15 genes. EC1002 also positive for aac(6)-Ib and blaTEM-1, and EC2474 was positive for blaCTX-M-55 and rmtB (Table 1).

Table 1.

Characteristics of Colistin-Resistant and Carbapenem-Resistant Escherichia coli Strains and Their Transconjugants

SpeciesEC1002Transconjugants
EC2474Transconjugants
J53
MCR-1NDM-1MCR-1NDM-1
Resistance genesMCR-1
blaNDM-1
blaCTX-M-14
aac(6′)-Ib
blaTEM-1
MCR-1blaNDM-1
aac(6′)-Ib
blaCTX-M-15
blaTEM-1
MCR-1
blaNDM-1
blaCTX-M-15
blaCTX-M-55
rmtB
MCR-1
blaCTX-M-15
blaNDM-1
blaCTX-M-55
NA
Sequence typeST2373NANAST131NANANA
Plasmid(s) size∼80 kb
∼105 kb
∼125 kb
∼210 kb
∼80 kb∼125 kb∼110 kb
∼130 kb
∼250 kb
∼250 kb∼110 kbNA
MIC of antimicrobial drug, μg/mLa
 Ampicillin>1288>128>128>128>1282
 Piperacillin-tazobactam64464>12864641
 Cefazolin>1282>128>128>128>1281
 Cefoxitin>1282>128>128>128>1281
 Ceftriaxone>1281>128>128>128>1280.064
 Cefepime>128132>128>128320.064
 Aztreonam64116>12816160.125
 Amikacin6416464220.25
 Gentamicin16116161610.5
 Tobramycin16116161610.5
 Ciprofloxacin0.50.250.2580.250.250.032
 Levofloxacin10.250.25810.250.032
 Ertapenem160.5816480.064
 Imipenem16116164160.125
 Meropenem160.5168480.064
 Tigecycline10.50.510.250.250.125
 Colistin440.5440.50.5
 Polymyxin B420.5440.50.25
SpeciesEC1002Transconjugants
EC2474Transconjugants
J53
MCR-1NDM-1MCR-1NDM-1
Resistance genesMCR-1
blaNDM-1
blaCTX-M-14
aac(6′)-Ib
blaTEM-1
MCR-1blaNDM-1
aac(6′)-Ib
blaCTX-M-15
blaTEM-1
MCR-1
blaNDM-1
blaCTX-M-15
blaCTX-M-55
rmtB
MCR-1
blaCTX-M-15
blaNDM-1
blaCTX-M-55
NA
Sequence typeST2373NANAST131NANANA
Plasmid(s) size∼80 kb
∼105 kb
∼125 kb
∼210 kb
∼80 kb∼125 kb∼110 kb
∼130 kb
∼250 kb
∼250 kb∼110 kbNA
MIC of antimicrobial drug, μg/mLa
 Ampicillin>1288>128>128>128>1282
 Piperacillin-tazobactam64464>12864641
 Cefazolin>1282>128>128>128>1281
 Cefoxitin>1282>128>128>128>1281
 Ceftriaxone>1281>128>128>128>1280.064
 Cefepime>128132>128>128320.064
 Aztreonam64116>12816160.125
 Amikacin6416464220.25
 Gentamicin16116161610.5
 Tobramycin16116161610.5
 Ciprofloxacin0.50.250.2580.250.250.032
 Levofloxacin10.250.25810.250.032
 Ertapenem160.5816480.064
 Imipenem16116164160.125
 Meropenem160.5168480.064
 Tigecycline10.50.510.250.250.125
 Colistin440.5440.50.5
 Polymyxin B420.5440.50.25

Abbreviations: MCR-1, plasmid-mediated colistin resistance; MIC, minimum inhibitory concentration; NA, not applicable; NDM-1, New Delhi metallo-β lactamase 1.

a In vitro antimicrobial susceptibility was performed by broth microdilution method, and the MICs were interpreted according to Clinical and Laboratory Standards Institute criteria, except for tigecycline, colistin, and polymyxin B, for which interpretations were performed according to the European Committee on Antimicrobial Susceptibility Testing guidelines.

Table 1.

Characteristics of Colistin-Resistant and Carbapenem-Resistant Escherichia coli Strains and Their Transconjugants

SpeciesEC1002Transconjugants
EC2474Transconjugants
J53
MCR-1NDM-1MCR-1NDM-1
Resistance genesMCR-1
blaNDM-1
blaCTX-M-14
aac(6′)-Ib
blaTEM-1
MCR-1blaNDM-1
aac(6′)-Ib
blaCTX-M-15
blaTEM-1
MCR-1
blaNDM-1
blaCTX-M-15
blaCTX-M-55
rmtB
MCR-1
blaCTX-M-15
blaNDM-1
blaCTX-M-55
NA
Sequence typeST2373NANAST131NANANA
Plasmid(s) size∼80 kb
∼105 kb
∼125 kb
∼210 kb
∼80 kb∼125 kb∼110 kb
∼130 kb
∼250 kb
∼250 kb∼110 kbNA
MIC of antimicrobial drug, μg/mLa
 Ampicillin>1288>128>128>128>1282
 Piperacillin-tazobactam64464>12864641
 Cefazolin>1282>128>128>128>1281
 Cefoxitin>1282>128>128>128>1281
 Ceftriaxone>1281>128>128>128>1280.064
 Cefepime>128132>128>128320.064
 Aztreonam64116>12816160.125
 Amikacin6416464220.25
 Gentamicin16116161610.5
 Tobramycin16116161610.5
 Ciprofloxacin0.50.250.2580.250.250.032
 Levofloxacin10.250.25810.250.032
 Ertapenem160.5816480.064
 Imipenem16116164160.125
 Meropenem160.5168480.064
 Tigecycline10.50.510.250.250.125
 Colistin440.5440.50.5
 Polymyxin B420.5440.50.25
SpeciesEC1002Transconjugants
EC2474Transconjugants
J53
MCR-1NDM-1MCR-1NDM-1
Resistance genesMCR-1
blaNDM-1
blaCTX-M-14
aac(6′)-Ib
blaTEM-1
MCR-1blaNDM-1
aac(6′)-Ib
blaCTX-M-15
blaTEM-1
MCR-1
blaNDM-1
blaCTX-M-15
blaCTX-M-55
rmtB
MCR-1
blaCTX-M-15
blaNDM-1
blaCTX-M-55
NA
Sequence typeST2373NANAST131NANANA
Plasmid(s) size∼80 kb
∼105 kb
∼125 kb
∼210 kb
∼80 kb∼125 kb∼110 kb
∼130 kb
∼250 kb
∼250 kb∼110 kbNA
MIC of antimicrobial drug, μg/mLa
 Ampicillin>1288>128>128>128>1282
 Piperacillin-tazobactam64464>12864641
 Cefazolin>1282>128>128>128>1281
 Cefoxitin>1282>128>128>128>1281
 Ceftriaxone>1281>128>128>128>1280.064
 Cefepime>128132>128>128320.064
 Aztreonam64116>12816160.125
 Amikacin6416464220.25
 Gentamicin16116161610.5
 Tobramycin16116161610.5
 Ciprofloxacin0.50.250.2580.250.250.032
 Levofloxacin10.250.25810.250.032
 Ertapenem160.5816480.064
 Imipenem16116164160.125
 Meropenem160.5168480.064
 Tigecycline10.50.510.250.250.125
 Colistin440.5440.50.5
 Polymyxin B420.5440.50.25

Abbreviations: MCR-1, plasmid-mediated colistin resistance; MIC, minimum inhibitory concentration; NA, not applicable; NDM-1, New Delhi metallo-β lactamase 1.

a In vitro antimicrobial susceptibility was performed by broth microdilution method, and the MICs were interpreted according to Clinical and Laboratory Standards Institute criteria, except for tigecycline, colistin, and polymyxin B, for which interpretations were performed according to the European Committee on Antimicrobial Susceptibility Testing guidelines.

The analysis of S1-PFGE demonstrated that plasmid profiles were diverse; EC1002 contained 4 plasmids, whereas EC2474 contained 3 plasmids, which ranged from 80 kb to 250 kb (Supplementary Data). Southern blotting confirmed that the MCR-1 gene was located on an approximately 80 kb plasmid in EC1002 and an approximately 250 kb plasmid in EC2474, whereas blaNDM-1 was located on an approximately 125 kb plasmid in EC1002 and an approximately 110 kb plasmid in EC2474 (Supplementary Data). The plasmids harboring the blaNDM-1 and MCR-1 genes were transferable to E. coli J53, which indicated that blaNDM-1 and MCR-1 were located on self-conjugative plasmids (Table 1).

Epidemic clone E. coli ST131 was associated with the global spread of blaCTX-M-15 [5]. In China, ST131 was the most common ST associated with extended-spectrum (ESBL)–producing E. coli [6]. The co-production of MCR-1 with NDM-5 or NDM-9 in Enterobacteriaceae has been reported very recently [7, 8]. Of particular concern is that our data further demonstrate the co-location of MCR-1 along with NDM-1 and ESBLs from clinical isolates. Interestingly, we found that both strains were still susceptible to tigecycline. However, tigecycline resistance in Enterobacteriaceae has been detected increasingly during treatment with this agent [9, 10]. This raises a concern that the pan-resistant E. coli may spread to clinical settings with ST131. Our study was limited by the relatively small number of patients with MCR-1– and NDM-1–producing E. coli. Thus, the close monitoring of colistin- and carbapenem-resistant Enterobacteriaceae from clinical isolates is warranted.

_supplementary Data

Supplementary materials are available at http://cid.oxfordjournals.org. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.

Notes

Acknowledgments. The authors thank the microbiology staff at both the Affiliated Hospital of Jining Medical University and Anhui Provincial Hospital. We also thank Dr Yunbo Chen, Miss Jinru Ji, and Miss Chaoqun Ying for their technical support in laboratory investigation.

Financial support. This work was supported by the National Basic Research Program of China (973 program, number 2015CB554201) and the National Natural Science Foundation of China (81361138021 and 81301461).

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1

de Jager
P
,
Chirwa
T
,
Naidoo
S
,
Perovic
O
,
Thomas
J
.
Nosocomial outbreak of New Delhi metallo-beta-lactamase-1-producing gram-negative bacteria in South Africa: a case-control study
.
PLoS One
2015
;
10
:
e0123337
.

2

Jain
A
,
Hopkins
KL
,
Turton
J
et al. .
NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases
.
J Antimicrob Chemother
2014
;
69
:
1777
84
.

3

Liu
YY
,
Wang
Y
,
Walsh
TR
et al. .
Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study
.
Lancet Infect Dis
2016
;
16
:
161
8
.

4

Gu
DX
,
Huang
YL
,
Ma
JH
et al. .
Detection of colistin resistance gene mcr-1 in hypervirulent Klebsiella pneumoniae and Escherichia coli isolates from an infant with diarrhea in China
.
Antimicrob Agents Chemother
2016
;
60
:
5099
100
.

5

Kim
YA
,
Qureshi
ZA
,
Adams-Haduch
JM
,
Park
YS
,
Shutt
KA
,
Doi
Y
.
Features of infections due to Klebsiella pneumoniae carbapenemase-producing Escherichia coli: emergence of sequence type 131
.
Clin Infect Dis
2012
;
55
:
224
31
.

6

Zhao
L
,
Zhang
J
,
Zheng
B
et al. .
Molecular epidemiology and genetic diversity of fluoroquinolone-resistant Escherichia coli isolates from patients with community-onset infections in 30 Chinese county hospitals
.
J Clin Microbiol
2015
;
53
:
766
70
.

7

Li
A
,
Yang
Y
,
Miao
M
et al. .
Complete sequences of mcr-1-harboring plasmids from extended spectrum beta-lactamase (ESBL)- and carbapenemase-producing Enterobacteriaceae (CPE)
.
Antimicrob Agents Chemother
2016
;
60
:
4351
4
.

8

Yao
X
,
Doi
Y
,
Zeng
L
,
Lv
L
,
Liu
JH
.
Carbapenem-resistant and colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1
.
Lancet Infect Dis
2016
;
16
:
288
9
.

9

Pournaras
S
,
Koumaki
V
,
Spanakis
N
,
Gennimata
V
,
Tsakris
A
.
Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance
.
Int J Antimicrob Agents
2016
;
48
:
11
8
.

10

Bogdanovich
T
,
Adams-Haduch
JM
,
Tian
GB
et al. .
Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258
.
Clin Infect Dis
2011
;
53
:
373
6
.

Author notes

a

B. Z., H. D., and H. X. contributed equally to this work.

Supplementary data